SubHero Banner

Inqovi® (decitabine/cedazuridine) – New orphan drug approval

July 7, 2020 - The FDA announced the approval of Astex Pharmaceuticals’ Inqovi (decitabine/cedazuridine), for treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System (IPSS) groups.

Download PDF